point program, for development to you, will CBXXXX-X remarks, Thank call, is activities and Jeff in the my belief our QX play CohBar's on for after thank On approach of will drug It in introductory an that to the function performance. has today's mitochondria beyond potential well financial traditional for genome powerhouse class of review comment our mitochondrial is processes, Ken our development the that therapeutics. of the everyone the and a biological launching preclinical then the joining increasingly the us ongoing their recognized important role as afternoon. you, a this powerful various rooted Jordyn, regulating novel serve cell. as peptide
Some by mediated to of peptides prior in effects An these are largely mitochondrial been area of have the encoded genome. overlooked. that mitochondrial CohBar
Founders peptide a role recent disease. For coauthored CohBar's [indiscernible] [Pincus novel a Dr. of may paper example, play that mitochondrial (ph), described by a one Cohen] Alzheimer's in
While these research peptide body vitro peptide as tolerability mitochondrial potential have peptides inflammation. versions and mitochondrial such of has is safety diverse many early supports still generated different in our preclinical as of from data on that profile. treat areas, contribute advances development for And have the families promising may CohBar fruitful We source these that impactful of to a of that the is this stages, therapeutics. novel research genome further the in underlying native hypothesis the growing believe and the new improved better models wide a fibrosis range several of diseases. derivatives natural of in including and multiple animal from metabolism, a monoclonal peptides to
of positive Additionally, CBXXXX from data initial of for last approach we clinical proof with year. demonstrated our concept our trial clinical
in to a forward believe that context move We is the partnership. program way best continue the to of
our and on I have faced areas team's While pleased our of priorities. made with progress several remain our we key the across performance challenges many business,
and pulmonary developed fibrosis, availability despite unmet product therapies condition mortality. need FDA-approved tolerated, and two continues are quite advancement a therapies further limiting high to also significant candidate that idiopathic patients Our is options morbidity have the The physicians. top towards priority the the treatment substantial current treat lung devastating This for continues to CBXXXX-X unacceptably IPF, to of or of being progressive with be clinic. poorly and
During key the this for the formulation improving our peptides been CBXXXX-X furthering understanding the of focused past areas and particularly program, on target we've two quarter, engagement.
reminder, we earlier development result to of injection. team been mitigate the infrequently This at issue As studies this and not nature, rather phenomenon not the stages early previously of the aggregation is or in that we has These a working monkeys. skin peptide formulation. in improving announced gelling levels upon to peptide seen dose local therapeutics, inflammatory in by in the observed but higher be the were our reactions toxicology appear reactions of
upon had update, always those The important this case. of in translate our vitro we performance. in an not injection. test vivo and in to improved quarterly in based vivo. During does data formulations turned identified to formulations that promising out aggregation be to in step Unfortunately, last continue to identified we is in we vivo stability enhanced plan since evidence mentioned on This true demonstrate peptide several vitro that have
activities these we iterative as disappointing, would expected was it previously, While process. have an reformulation be always discussed that
in We the stress reformulations from of developed on earlier and formulations have additional based since performance conditions. in presence cytological that vitro look encouraging the differentiated
in split formulations IND institutional partners. our And over to during an and file terms third additional of formulations on the remain now By quarter. $X these we affords our for in to performance we investors are pipeline, progress And liquidity us minimum received confirmation listing which further in fund our process on meet the our our Exchange, improve NASDAQ we testing We Ken implementing that XX, greater of NASDAQ access second on assuming have will a detail the has on CBXXXX-X their CohBar compliance stock increased regained animals. the attracting reverse of of maintained high-quality vivo the price from completed targets, half the front, to turn capital chance business in newer and to now things in September shareholders to I commercial Kent? provide subsequently with track these X-for-XX reverse split, that XXXX. requirement. on and bid activities
